Abstract
Several commercial assays for SARS-CoV-2 RT-PCR are available but few of them were assessed. We evaluate the Allplex 2019-nCoV (Seegene) assay using 41 nasopharyngeal samples. The rates of agreement were 92.7% and 100% with the GeneFinder COVID-19 plus (Elitech) and the diagnosis of the infectious disease specialist respectively. Four samples display a Ct < 22.0 for the E and RdRp genes while the N gene was not detected, suggesting a variability of the viral sequence. There was no cross-reactivity with other respiratory viruses. The Allplex 2019-nCoV appears as a reliable method, but additional evaluations using more samples are needed. RT-PCR assays should probably include at least 2 viral targets.
Keywords:
Allplex 2019-nCoV (Seegene); COVID-19; Nasopharyngeal swab; RT-PCR; SARS-CoV-2; Sensitivity.
MeSH terms
-
Betacoronavirus / genetics*
-
COVID-19
-
COVID-19 Testing
-
Clinical Laboratory Techniques / methods
-
Coronavirus Envelope Proteins
-
Coronavirus Infections / diagnosis*
-
Coronavirus Nucleocapsid Proteins
-
Coronavirus RNA-Dependent RNA Polymerase
-
France
-
Humans
-
Nasopharynx / virology
-
Nucleocapsid Proteins / genetics*
-
Pandemics
-
Phosphoproteins
-
Pneumonia, Viral / diagnosis*
-
Prospective Studies
-
RNA-Dependent RNA Polymerase / genetics*
-
Reverse Transcriptase Polymerase Chain Reaction / methods*
-
SARS-CoV-2
-
Viral Envelope Proteins / genetics*
-
Viral Nonstructural Proteins / genetics*
Substances
-
Coronavirus Envelope Proteins
-
Coronavirus Nucleocapsid Proteins
-
Nucleocapsid Proteins
-
Phosphoproteins
-
Viral Envelope Proteins
-
Viral Nonstructural Proteins
-
envelope protein, SARS-CoV-2
-
nucleocapsid phosphoprotein, SARS-CoV-2
-
Coronavirus RNA-Dependent RNA Polymerase
-
NSP12 protein, SARS-CoV-2
-
RNA-Dependent RNA Polymerase